CGON
CG Oncology, Inc.Price
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Mar 16 ▼ 1 insider sell $124.7K at $63.50
- Apr 17 ▼ 1 insider sell $1.1M at $73.01
- Jun 4 ▼ 1 insider sell $54.5K at $54.50
- Jun 15 to Jun 24 ▼ 3 days of insider sells: $793.1K by 2 insiders, avg $66.29
- Jun 25 ▲ 1 insider buy $24.8M at $66.87
- Jul 10 to Jul 15 ▼ 2 days of insider sells: $1.9M by 2 insiders, avg $75.00
- Jul 27 FDA: CG Oncology Announces Publication of Pivotal Phase 3 BOND-…
- Aug 6 ▼ CG Oncology reported Q2 2026 EPS of -$0.90, significantly wider than…
- Aug 6 ▼ CG Oncology upsized its at-the-market (ATM) equity offering by $500M…
- Aug 14 ▼ 1 insider sell $74.5K at $74.54
- Sep 15 ▼ 1 insider sell $73.0K at $72.98
- Oct 15 ▼ 1 insider sell $62.1K at $62.07
- Nov 16 New report: subscribers see the details Unlock
- Nov 16 New catalyst: subscribers see the details Unlock
Signal stack
Where each data set points today.
- InsidersBULLISH
1 insider bought $24.8M at an average $66.87. 2 insiders sold $4.2M. Price is 27% above their cost.
- InstitutionsBULLISH
Q3 2026: 27 added (2 new), 14 trimmed or exited. Largest new: Public Sector Pension Investment Board $11.4M.
- AnalystsBULLISH
19 of 21 rate it Buy or better.
- Short sellersSTEADY
Short interest +3.9% to 9.22M shares. 11.0 days to cover, ≈10.3% of shares.
- TrendUPTREND
24% above its 50-day average. New closing high $84.78 on Nov 16.
Who's buying
13F· Q3 2026| Fund | Move | Value |
|---|---|---|
| MORGAN STANLEY | ADD | $106.3M |
| BNP PARIBAS FINANCIAL MARKETS | ADD | $37.1M |
| Russell Investments Group, Ltd. | ADD | $17.6M |
| MASSACHUSETTS FINANCIAL SERVICES CO /MA/ | ADD | $15.6M |
| PUBLIC SECTOR PENSION INVESTMENT BOARD | NEW | $11.4M |
| DEUTSCHE BANK AG\ | TRIM | $10.1M |
| Invesco Ltd. | DOUBLED | $10.1M |
| ALPS ADVISORS INC | ADD | $8.3M |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
21 analysts| Date | Firm | Rating |
|---|---|---|
| Nov 9, 2026 | Guggenheim MAINTAIN | Buy |
| Nov 6, 2026 | Wedbush MAINTAIN | Outperform |
| Aug 7, 2026 | RBC Capital MAINTAIN | Outperform |
| Aug 7, 2026 | Piper Sandler MAINTAIN | Overweight |
| Aug 7, 2026 | Truist Securities MAINTAIN | Buy |
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
Kalofonos Isabel Chief Commercial Officer Oct 15, 2026 | AWARD | 92,000 sh |
POST LEONARD E Director Oct 15, 2026 | SELL | $30.8K |
POST LEONARD E Director Oct 15, 2026 | SELL | $31.2K |
POST LEONARD E Director Oct 15, 2026 | EXERCISE | $600.00 |
POST LEONARD E Director Sep 15, 2026 | SELL | $73.0K |
POST LEONARD E Director Sep 15, 2026 | EXERCISE | $600.00 |
POST LEONARD E Director Aug 14, 2026 | SELL | $74.5K |
POST LEONARD E Director Aug 14, 2026 | EXERCISE | $600.00 |
Earnings setup
EstimatesRevision history: 🔒 Fresh data, subscribers only
| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | 🔒 Fresh data, subscribers only | |||
| Next Q | 🔒 Fresh data, subscribers only | |||
| Current FY | 🔒 Fresh data, subscribers only | |||
| Next FY | 🔒 Fresh data, subscribers only | |||
Short side
FINRA· Oct 30, 2026SecBot reports
20 filings · 5 press releases · 4 bullish · 3 bearish · 2 mixed · 11 neutral- BULLISH 8-KNov 16, 2026
CG Oncology announced positive topline results from its Phase 3 PIVOT-006 trial of cretostimogene in intermediate-risk and high-grade Ta NMIBC, showing a 68% reduction in recurrence risk (HR 0.32, p<0.0001) with no Grade 3+ TRAEs. The company also updated BLA timelines: completion of the…
🔒 Fresh report (last 24h), subscribers only
- BULLISH PRESS RELEASENov 16, 2026
CG Oncology reported positive topline results from the PIVOT-006 Phase 3 trial of cretostimogene in intermediate-risk and high-grade Ta NMIBC, showing a 68% reduction in recurrence risk (HR 0.32, p<0.0001) with no Grade 3+ TRAEs. The company plans to broaden its initial BLA submission in…
🔒 Fresh report (last 24h), subscribers only
- BEARISH 8-KNov 6, 2026
CG Oncology reported Q3 2026 net loss of $56.9M ($0.64 per share), wider than the $43.8M loss a…
The stock will be driven by upcoming clinical data readouts (PIVOT-006 topline this month, 12-month data in December) and BLA completion timing. Monitor these catalysts for potential inflection; the…
- NEUTRAL PRESS RELEASENov 6, 2026
CG Oncology reported Q3 2026 financial results showing a net loss of $56.9 million ($0.64 per…
The next major catalyst is PIVOT-006 topline data in November 2026, which could significantly impact the stock if positive or negative. Also watch for BLA submission completion in Q4 2026 and…
All CGON filing & press-release reports (25)
- 8-K reportNov 16, 2026
- PRESS-RELEASE reportNov 16, 2026
- 8-K reportNov 6, 2026
- PRESS-RELEASE reportNov 6, 2026
- INST-CLUSTER reportNov 3, 2026
- 3 reportOct 19, 2026
- 144 reportOct 15, 2026
- INST-CLUSTER reportOct 12, 2026
- PRESS-RELEASE reportAug 6, 2026
- 424B5 reportAug 6, 2026
- PRESS-RELEASE reportJul 27, 2026
- CLUSTER reportJul 17, 2026
- COURT-RULING reportJul 16, 2026
- 144 reportJun 24, 2026
- 144 reportJun 22, 2026
- INST-CLUSTER reportJun 12, 2026
- 8-K reportMay 26, 2026
- PRESS-RELEASE reportMay 15, 2026
- 8-K reportMay 8, 2026
- PRESS-RELEASE reportMay 8, 2026
- DEFA14A reportApr 24, 2026
- 144 reportApr 17, 2026
- 8-K reportApr 13, 2026
- INST-CLUSTER reportFeb 28, 2026
- PRESS-RELEASE reportFeb 27, 2026